Iterum Therapeutics reports Q2 non-GAAP EPS (13c) vs. (23c) last year

“We are on track to launch ORLYNVAH this month for the treatment of uncomplicated urinary tract infections,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics (ITRM). “We’re proud to introduce the first branded antibiotic for uUTIs in over 25 years-a critical milestone as rising antimicrobial resistance has rendered many commonly used generic treatments ineffective across large parts of the U.S. ORLYNVAH is the only Food and Drug Administration approved oral penem antibiotic in the U.S., offering a much-needed option for patients with limited alternatives due to resistant Gram-negative bacteria, including extended spectrum ss-lactamases-producing Enterobacterales.”